Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fuji Pharma to File Biosimilars for Japan Approval by 2021: President
May 20, 2019
- JCR to License Lysosome Storage Disease Treatment to Global Player by March 2020: Chairman
May 20, 2019
- Ohara Join Hands with Nigerian Pharma, Eying Future Population Growth in Africa
May 17, 2019
- Suzuken to Exclusively Distribute Kymriah in Japan
May 17, 2019
- 21 Japan Drug Makers’ Combined Sales Up 5% in FY2018, but Flagging Japan Biz Continues
May 16, 2019
- Daiichi Sankyo’s Quizartinib Voted Down by US FDA Advisory Committee
May 16, 2019
- Yutaka Ogihara, Grandson of Founder Hiroshi Ogihara, to Lead Kyorin Holdings
May 16, 2019
- Takeda Sees 18.5% Sales Rise after Shire Buy, but Braces for Losses in FY2019
May 15, 2019
- Nichi-Iko Aims at Overseas Sales of 60 Billion Yen in FY2021; Infliximab Biosimilar in the US to Play Key Role
May 15, 2019
- AnGes Delays Launch of Collategene, “Sale Preparations Will Take More Time”
May 15, 2019
- Nichi-Iko Reduces Its Stake in Aprogen, Biz Tie-Up to Stay
May 14, 2019
- US PII Study for Telomelysin-Keytruda Combo Begins for Esophageal Cancer
May 14, 2019
- Nichi-Iko Aims to Resume Stable Supply of Cefazolin by Year-End: Exec
May 14, 2019
- Avastin Top Selling Drug in Japan in April: Encise Snapshot
May 14, 2019
- Japan Ethical Drug Sales Up 0.5% in March: Crecon
May 14, 2019
- Kyorin Grabs Japan Negotiation Rights to Marketing Collaboration for MSD’s Cough Treatment
May 14, 2019
- Daiichi Sankyo’s Hypertension Drug Minnebro Now Available
May 14, 2019
- Eisai’s FY2018 Net Profit Jumps 22.3% on Merck Deal, Global Brands
May 14, 2019
- Sumitomo Dainippon’s Sales Down 1.6% on Price Cuts, Generic Erosions
May 13, 2019
- Sunovion to Push Different Dasotraline Trial Data in FDA Negotiations: Sumitomo Dainippon Chief
May 13, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…